Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
As of today (2026-08-15), Abbisko Cayman's Volatility is 73.69%.
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Abbisko Cayman Volatility Related Terms
HKSE:02256 vs VRTX, REGN, RVMD: Volatility Comparison
For the Biotechnology subindustry, Abbisko Cayman's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman Volatility vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Volatility distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's Volatility falls into.
The annualized volatility is calculated as following:
σA
=
σM
*
√12
=
√ 1/(n-1) ∑(Ri - R')^2
*
√12
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (HKSE:02256) has a Volatility of 73.69% as of Aug. 15, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Abbisko Cayman and its competitors.
Is Abbisko Cayman's Volatility too high?
Abbisko Cayman's current Volatility is 73.69%. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Volatility compare to VRTX and REGN?
Abbisko Cayman's Volatility of 73.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Abbisko Cayman and its competitors. Abbisko Cayman's current Volatility is 73.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current Volatility is 73.69%. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current Volatility is 73.69% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30.
GuruFocus considers Abbisko Cayman to be Modestly Undervalued.
Key valuation signals for HKSE:02256:
Volatility: 73.69%
GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score
Get the complete analysis for HKSE:02256
Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02256 has been successfully added to your 
